Regeneron Pharmaceutical Inc. said Thursday that a clinical trial of its REGN-COV candidate treatment for Covid-19 met the drug's primary endpoint of significantly reducing viral load within seven days in hospitalized patients.
Regeneron said that the drug, an antibody cocktail of casirivimab and imdevimab, reduced the risk of death by 36% about a month after treatment began in the study's patient population.
The Phase 2/3 trial included 1,197 patients hospitalized with Covid-19, including some using supplemental oxygen and some who weren't. Patients got either a placebo, or one of two dose levels of REGN-COV.
REGN-COV hasn't been approved by the Food and Drug Administration, but its use has been authorized in some high-risk patients for treatment and post-exposure prophylaxis. Regeneron shares climbed 2.2% in pre-market trading.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.